Nitric oxide inhalation can significantly improve oxygen supply in newborn babies with pulmonary hypertension according to a study published in the journal European Review for Medical and Pharmacological Sciences.
Researchers have identified a noninvasive way to predict disease outcomes in patients with pulmonary arterial hypertension (PAH) that uses three-dimensional measures of the right heart ventricle. The method allows physicians to assess the risk of deterioration without exposing patients to repetitive heart catheterization — and may offer a way to…
Chinese scientists have identified a large number of proteins that are differentially expressed in the blood of people with pulmonary arterial hypertension associated with congenital heart disease (CHD-PAH), for the first time.
Sildenafil appears to treat pulmonary hypertension (PH) by reducing the recruitment of bone marrow (BM)-derived progenitor cells, cells now being seen as potential key drivers of lung remodeling and inflammation in diseases that include PH. The study, “Sildenafil attenuates hypoxic pulmonary remodelling by inhibiting bone marrow progenitor cells,” was published in the…
Measures of pulmonary arterial capacitance (PAC) may help to predict the risk of heart problems in patients with pulmonary hypertension caused by left heart disease. But before the method might be applied in the clinic, studies are needed to confirm its usefulness. The study, “Pulmonary Arterial Capacitance Predicts Cardiac Events in…
The specific benefits of balloon pulmonary angioplasty (BPA) on the respiratory function of patients with chronic thromboembolic pulmonary hypertension (CTEPH) depends on what area of the lung, or lung field, the procedure is performed on, according to new research. This finding was published in the article “Effect Of Balloon Pulmonary Angioplasty…
November is Pulmonary Hypertension Awareness Month and, in recognition, SteadyMed has announced the launch of its new website, BePHenomenal.com, dedicated to educating people with pulmonary hypertension (PH) so as to empower them to live the healthiest and most PHenomenal lives possible. The Pulmonary Hypertension Association notes…
Researchers suggest that a protein called ED-A+ Fn (ED-A domain containing fibronectin) could serve as a marker for pulmonary hypertension (PH), aiding in diagnosis and allowing better monitoring of treatment responses. The study, “Lung tissue remodelling in MCT-induced pulmonary hypertension: a proposal for a novel scoring system and…
The U.S. Food and Drug Administration (FDA) has designed Reviva Pharmaceuticals’ RP5063 an Orphan Drug as a potential treatment of pulmonary arterial hypertension (PAH), providing the company with developmental and testing assistance. “We are pleased to receive Orphan Drug Designation for RP5063, which emphasizes the significant need for new mediations for patients…
Medications that specifically trigger cell death in remodeled blood vessels, without damaging the heart or healthy blood vessels, may be used to treat pulmonary arterial hypertension (PAH), researchers suggest. Their study, “Apoptosis-based therapy to treat pulmonary arterial hypertension,” published in the Journal of Rare Diseases Research & Treatment,…
Physical exercise can modulate the immune response that activates inflammation in patients with idiopathic pulmonary arterial hypertension to improve their cardiopulmonary function and quality of life, a study published in the BMC Pulmonary Medicine reported. Pulmonary arterial hypertension (PAH) is a progressive vascular disease characterized by increased blood pressure in the lung vasculature,…
ProMetic Life Sciences recently presented positive preclinical data on its fibrosis-targeting lead candidate, PBI-4050, showing that the drug effectively reduces pulmonary hypertension and right ventricular hypertrophy. The company also presented positive effects of PBI-4050 on cardiovascular biomarkers in patients with metabolic syndrome and type 2 diabetes. The data…
Get regular updates to your inbox.
